INDIA GLYCOLS LIMITED

DNV
ISO 9001, ISO 14001, ISO 45001, ISO 50001

Plot No. 2-B, Sector - 126, NOIDA-201304, Distt. Gautam Budh Nagar (Uttar Pradesh), Tel. : +91 (120) 6860000, 3090100, 3090200
Fax : +91 (120) 3090111, 3090211, E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

IGL/SE/2026-27/36

12th August, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Scrip Code: 500201

Symbol: INDIAGLYCO

Dear Sirs,

<u>Sub: Outcome of the Board Meeting held on 12th August, 2026</u>

Further to our letter no. IGL/SE/2026-27/34 dated 5th August, 2026 and pursuant to Regulation 30 and Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today i.e. 12th August, 2026 has, inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended 30th June, 2026.

A copy of Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended 30th June, 2026 along with the Limited Review Report of Statutory Auditors thereon are enclosed herewith.

The above said Board Meeting commenced at 15:45 Hrs. and concluded at 16:50 Hrs.

This is for your information and record.

Thanking you,

Yours truly,
For India Glycols Limited

ANKUR
JAIN

Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a

CORPORATE OFFICE : 3A, Shakespeare Sarani, Kolkata - 700071, West Bengal, Phone : +91 (33) 22823585, 22823586
REGISTERED OFFICE : A-1 Industrial Area, Bazpur Road, Kashipur - 244713, Distt. Udham Singh Nagar (Uttarakhand)
Phone : +91 (5947) 269000, 269500, Fax : +91 (5947) 275315, 269535
CIN : L24111UR1983PLC009097

INDIA GLYCOLS LIMITED

Regd. Office ; A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand)
Phones: +91 5947 269000/ 269500., Fax: +91 5947 275315/ 269535
Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com
CIN No.L24111UR1983PLC009097

Statement Of Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026 (₹ In Crores, except as stated)

S.No	Particulars	Standalone				Consolidated			
		Quarter ended			Year ended	Quarter ended			Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited) (Refer Note-3)	30.06.2025 (Unaudited)	31.03.2026 (Audited)	30.06.2026 (Unaudited)	31.03.2026 (Audited) (Refer Note-3)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	**Income from operations**								
	(a) Revenue from operations	2,986.92	2,361.40	2,503.03	9,826.20	2,988.44	2,360.01	2,503.12	9,826.63
	(b) Other income	0.38	39.20	1.40	43.51	0.38	0.62	1.40	4.93
	Total income	2,987.30	2,400.60	2,504.43	9,869.71	2,988.82	2,360.63	2,504.52	9,831.56
2	**Expenses**								
	(a) Cost of materials consumed	678.45	484.66	669.10	2,412.43	678.45	484.66	669.10	2,412.43
	(b) Purchase of stock-in-trade	29.11	40.25	44.19	188.46	30.30	38.79	44.34	187.22
	(c) Changes in inventories of finished goods, Stock-in Trade and work-in-progress	(11.33)	83.51	(35.97)	60.92	(11.33)	83.51	(35.97)	62.35
	(d) Excise Duty	1,858.05	1,383.66	1,462.66	5,615.22	1,858.05	1,383.66	1,462.66	5,615.22
	(e) Employee benefits expense	37.02	33.68	30.60	130.69	37.53	34.21	31.06	132.61
	(f) Finance Costs	25.18	26.41	44.68	167.18	25.18	26.41	44.68	167.18
	(g) Depreciation and amortisation expense	42.48	41.23	34.45	155.38	42.48	41.23	34.45	155.38
	(h) Power and fuel	115.42	87.69	91.53	400.50	115.42	87.69	91.53	400.50
	(i) Other Expenses	110.28	83.73	93.06	371.40	110.46	80.99	90.76	367.05
	Total Expenses	2,884.66	2,264.82	2,434.30	9,502.18	2,886.54	2,261.15	2,432.61	9,499.94
	Profit Before Interest, Depreciation and Tax (EBITDA)	170.30	203.42	149.26	690.09	169.94	167.12	151.04	654.18
3	**Profit / (Loss) from operations before exceptional items and tax (1-2)**	**102.64**	**135.78**	**70.13**	**367.53**	**102.28**	**99.48**	**71.91**	**331.62**
4	Exceptional Items	-	-	-	0.83	-	-	-	0.83
5	**Profit / (Loss) before Tax (3-4)**	**102.64**	**135.78**	**70.13**	**366.70**	**102.28**	**99.48**	**71.91**	**330.79**
6	**Share of net profit/ (loss) of Joint Venture**	-				20.60	12.98	18.62	46.42
7	**Profit / (Loss) before Tax (5+6)**	**102.64**	**135.78**	**70.13**	**366.70**	**122.88**	**112.46**	**90.53**	**377.21**
8	Tax expense :								
	(a) Current Tax	13.27	(9.13)	7.57	21.07	13.27	(9.05)	7.57	21.15
	(b) Deferred Tax	12.78	34.63	9.71	63.30	12.78	34.63	9.71	63.30
9	**Profit / (Loss) after tax for the period (7-8)**	**76.59**	**110.28**	**52.85**	**282.33**	**96.83**	**86.88**	**73.25**	**292.76**
10	Other Comprehensive Income								
	A (i) Items that will not be reclassified to Profit or Loss	(0.25)	(1.52)	(0.25)	(2.27)	(0.21)	(1.21)	(0.37)	(2.33)
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	0.06	0.38	0.06	0.57	0.05	0.31	0.09	0.59
	B (i) Items that will be reclassified to Profit or Loss					0.01	0.10	(0.15)	0.12
	(ii) Income tax relating to items that will be reclassified to Profit or Loss								
	Other Comprehensive Income (Net of Tax)	**(0.19)**	**(1.14)**	**(0.19)**	**(1.70)**	**(0.15)**	**(0.80)**	**(0.43)**	**(1.62)**
11	**Total comprehensive income / (loss) for the period (9+10)**	**76.40**	**109.14**	**52.66**	**280.63**	**96.68**	**86.08**	**72.82**	**291.14**

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

12	**Net Profit/ (Loss) attributable to** (a) Owners of the Company (b) Non Controlling interest					96.83 -	86.88 -	73.25 -	292.76 -
13	**Other Comprehensive Income attributable to** (a) Owners of the Company (b) Non Controlling interest					(0.15) -	(0.80) -	(0.43) -	(1.62) -
14	**Total Comprehensive Income attributable to** (a) Owners of the Company (b) Non Controlling interest					96.68 -	86.08 -	72.82 -	291.14 -
15	Paid-up Equity Share Capital (Face value Rs. 5/- each)	33.51	33.51	30.96	33.51	33.51	33.51	30.96	33.51
16	Other Equity				2,503.93	-	-	-	2,899.27
17	**Earnings per equity share (face value of Rs 5/- each) Not annualised (In Rs.)** (a) Basic (b) Diluted	11.43 11.43	17.31 17.31	8.53 8.53	44.31 44.31	14.45 14.45	13.64 13.64	11.83 11.83	45.95 45.95

Unaudited Segment wise Revenue, Results and Assets and Liabilities		**Standalone**				**Consolidated**			
S.No	**Particulars**	**Quarter ended**			**Year ended**	**Quarter ended**			**Year ended**
		30.06.2026 (Unaudited)	**31.03.2026 (Audited) (Refer Note-3)**	**30.06.2025 (Unaudited)**	**31.03.2026 (Audited)**	**30.06.2026 (Unaudited)**	**31.03.2026 (Audited) (Refer Note-3)**	**30.06.2025 (Unaudited)**	**31.03.2026 (Audited)**
1	**Segment Revenue**								
	- Bio-based Specialities and Performance Chemicals	361.73	302.55	299.90	1,202.07	363.25	301.16	299.99	1,202.50
	- Potable Spirits	2,218.67	1,690.09	1,805.06	6,946.43	2,218.67	1,690.09	1,805.06	6,946.43
	- Ennature Biopharma	83.30	63.49	50.50	207.77	83.30	63.49	50.50	207.77
	- Bio- Fuel	323.22	305.27	347.57	1,469.93	323.22	305.27	347.57	1,469.93
	Total	**2,986.92**	**2,361.40**	**2,503.03**	**9,826.20**	**2,988.44**	**2,360.01**	**2,503.12**	**9,826.63**
2	Segment Results (Profit / (Loss) before Interest and Tax)								
	- Bio-based Specialities and Performance Chemicals	31.75	34.47	30.82	138.27	31.39	36.76	32.60	140.95
	- Potable Spirits	75.03	67.78	72.33	284.93	75.03	67.78	72.33	284.93
	- Ennature Biopharma	7.25	3.01	1.20	7.23	7.25	3.01	1.20	7.23
	- Bio- Fuel	27.03	30.21	22.67	115.23	27.03	30.21	22.67	115.23
	Total	**141.06**	**135.47**	**127.02**	**545.66**	**140.70**	**137.76**	**128.80**	**548.34**
	Less/Add :								
	- Interest (Net)	25.18	26.41	44.68	167.18	25.18	26.41	44.68	167.18
	- Exceptional items	-	-	-	0.83	-	-	-	0.83
	- Unallocated corporate expenses net of unallocable income	13.24	(26.72)	12.21	10.95	13.24	11.87	12.21	49.54
	Profit before share of profit / (Loss) from joint venture and exceptional items	**102.64**	**135.78**	**70.13**	**366.70**	**102.28**	**99.48**	**71.91**	**330.79**
	Share of profit/(loss) of Joint Venture	-	-	-	-	20.60	12.98	18.62	46.42
	Profit Before Tax	**102.64**	**135.78**	**70.13**	**366.70**	**122.88**	**112.46**	**90.53**	**377.21**
3	**Segment assets**								
	- Bio-based Specialities and Performance Chemicals	3,514.26	3,595.99	3,435.48	3,595.99	3,518.34	3,600.59	3,438.79	3,600.59
	- Potable Spirits	632.16	596.60	601.32	596.60	632.16	596.60	601.32	596.60
	- Ennature Biopharma	417.28	426.42	451.50	426.42	417.28	426.42	451.50	426.42
	- Bio- Fuel	1,538.06	1,429.96	1,245.56	1,429.96	1,538.06	1,429.96	1,245.56	1,429.96
	- Unallocated	44.35	77.15	104.21	77.15	456.94	469.38	507.00	469.38
	Total	**6,146.11**	**6,126.12**	**5,838.07**	**6,126.12**	**6,562.78**	**6,522.95**	**6,244.17**	**6,522.95**

N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

4	**Segment liabilities**								
	- Bio-based Specialities and Performance Chemicals	577.54	737.05	766.87	737.05	578.26	737.97	767.65	737.97
	- Potable Spirits	385.41	326.53	339.25	326.53	385.41	326.53	339.25	326.53
	- Ennature Biopharma	107.57	92.49	72.84	92.49	107.57	92.49	72.84	92.49
	- Bio- Fuel	100.20	92.27	93.59	92.27	100.20	92.27	93.59	92.27
	- Unallocated	2,361.55	2,340.34	2,641.81	2,340.34	2,361.87	2,340.91	2,642.13	2,340.91
	Total	**3,532.27**	**3,588.68**	**3,914.36**	**3,588.68**	**3,533.31**	**3,590.17**	**3,915.46**	**3,590.17**

Notes:

1 The above results were reviewed by the Audit committee in its meeting held on August 12, 2026 and have been approved by the Board of Directors in its meeting held on August 12, 2026. The auditors of the Company have carried out a limited review of the same.

2 Financial results have been prepared and presented in accordance with the recognition and measurement principles prescribed under Section 133 of the Companies Act, 2013.

3 The figures for the quarter ended March 31,2026 are the balancing figures between audited figures in respect of full financial year and unaudited year to date figures upto third quarter of FY 2025-26.

4 The Board of Directors of the Company at its meeting held on 4th February 2025, had approved the Composite Scheme of Arrangement ("Scheme") involving amalgamation of Kashipur Holdings Limited ("KHL") into the Company and Demerger of the Bio Pharma undertaking into a separate undertaking, namely, Ennature Bio Pharma Limited and Spirits & Biofuel Undertaking into a separate undertaking, namely, IGL Spirits Limited ("Demerger") to be listed on both the stock exchanges. Further, the Scheme was subject to the requisite approvals and sanction of the jurisdictional bench of National Company Law Tribunal and also subject to the approval of the shareholders and / or creditors of IGL, Central Government, or such other competent authority or intermediaries or agencies etc., as may be directed by the NCLT.

Further, post deliberations, to continue value creation for its stakeholders, the Board of Directors in its meeting held on 16th May 2025 had decided to exclusively focus on Demerger as described in the above paragraph. The earlier proposal for the amalgamation of KHL into the Company will no longer form part of the Scheme being pursued. The proposed modification does not affect any stakeholders, including shareholders, creditors, or employees. There will be no adverse implication on the existing public shareholders of Transferee Company as they will continue to own the same percentage of shares in the Company. The appointed date for the Scheme of Arrangement is 1st April, 2026.

The Company had filed applications with the Stock Exchanges for their No Objection/Observation Letters on the Scheme of Arrangement and received No Objection/Observation Letters from National Stock Exchange of India Limited and BSE Limited on 17th and 19th November, 2025, respectively. Thereafter, the Company had filed its First Motion Application before the Hon'ble NCLT, Allahabad Bench, Prayagraj ("NCLT"). The NCLT has allowed the application inter-alia, vide Order dated 15th January, 2026 read with Order dated 16th February 2026, has directed the Company to convened separate meetings of Equity Shareholders and Unsecured Creditor on 24th March, 2026 at which the Scheme was duly approved.

Thereafter, the Companies filed a joint application with the NCLT under the provisions of the Companies Act, 2013 for sanction of the Scheme. The application was admitted by the NCLT vide its Order dated 9th April 2026, and the matter was scheduled for further hearing on 21st May 2026, however the same was not taken up for hearing due to paucity of time. On 2nd July, 2026, the NCLT heard the matter and reserved its order, and the NCLT pronounced its decision vide Order dated 17th July, 2026 for sanctioning the Scheme. The Company has applied for the certified true copy of the NCLT Order and the same is awaited.

The above events do not have any impact or bearings on the financial results of the Company. Further, Key details of 3 companies for the quarter ended June 30,2026 are as under:-

Company Name	Revenue from operations	EBITDA
India Glycols Limited	354.64	40.22
IGL Spirits Limited	2,541.89	120.10
Ennature Bio Pharma Limited	90.39	9.98

5 Other Income (Standalone) for the quarter & year ended 31 March 2026 includes Dividend Income of Rs 38.58 crores from Subsidiary & Joint Venture companies.

6 The figures of the previous period/year have been restated/regrouped wherever necessary, to make them comparable.

for INDIA GLYCOLS LIMITED

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

INDIA GLYCOLS LIMITED NOIDA

U.S. BHARTIA
Chairman and Managing Director
DIN: 00063091

Place : Noida
Date : 12th August, 2026

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of India Glycols Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **India Glycols Limited ("the Company")** for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015; as amended ("the Listing Regulations").

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS), "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ('Ind-AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **K. N. GUTGUTIA & CO.**
Chartered Accountants
FRN: 304153E

Bhagat Ram Goyal
Digitally signed by Bhagat Ram Goyal
Date: 2026.08.12 16:46:48 +05'30'

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

(B.R. Goyal)
Partner
M.NO. 012172
UDIN: 26012172PHFMBT1261

Place: New Delhi
Dated: 12th August 2026

K.N. GUTGUTIA & CO.
CHARTERED ACCOUNTANTS
NEW DELHI : KOLKATA

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
India Glycols Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **India Glycols Limited ("the Holding Company")** and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its share of the net Profit after tax and total comprehensive income of its joint venture for the quarter ended 30th June, 2026 ("the statement") attached herewith being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

5. The Statement includes the results of the following entities:

Subsidiaries

i) IGL Finance Limited
ii) IGL Chem International Pte. Ltd., Singapore
iii) IGL Chem International USA LLC
iv) IGL Chemicals And Services Private Limited
v) Ennature Bio Pharma Limited (Formerly known as Ennature Bio Pharma Private Limited)
vi) IGL Spirits Limited

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

11-K, GOPALA TOWER, 25, RAJENDRA PLACE, NEW DELHI-110008
Phones : 25713944, 25788644, 25818644
E-mail : brg1971@cakng.com, kng1971@yahoo.com
Website : www.cakng.com

Joint Ventures

i) Clariant IGL Specialty Chemicals Private Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statement includes the Group's share of net profit after tax of ₹20.60 crores and total comprehensive income of ₹20.63 crores, for the quarter ended on 30 June 2026 as considered in the Statement, in respect of one joint venture whose Interim financial information have not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this joint venture is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 and 4 above.

   Our conclusion is not modified in respect of this matter.

For **K. N. GUTGUTIA & CO.**
Chartered Accountants
FRN 304153E

Bhagat Ram Goyal
Digitally signed by Bhagat Ram Goyal
Date: 2026.08.12 16:45:37 +05'30'

K.N. GUTGUTIA & CO. NEW DELHI CHARTERED ACCOUNTANTS

(B. R. Goyal)
Partner
M.NO. 012172
UDIN : 26012172FMXMTU7218

Dated: 12th August 2026
Place: New Delhi